Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities between February 5, 2025, and July 23, 2025, of the December 2, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Molina securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [2]. - The lawsuit alleges that Molina failed to disclose several material adverse facts regarding its financial health and operational assumptions, which misled investors [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [3]. - The firm has been recognized for its leadership in securities class action settlements, achieving notable recoveries, including over $438 million in 2019 alone [3]. Group 3: Case Specifics - The lawsuit claims that Molina's financial guidance for fiscal year 2025 was likely to be cut due to undisclosed adverse facts, which included issues with medical cost trend assumptions and a dislocation between premium rates and medical costs [4]. - The misleading positive statements made by Molina regarding its business operations and prospects are central to the claims made in the lawsuit [4].

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”), of the important January 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Firefly Aerospace Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Investigation and Legal Action - Shareholders who purchased Firefly Aerospace securities may be entitled to compensation through a contingency fee arrangement, with a class action being prepared to seek recovery of investor losses [2]. - The investigation follows a report from The Wall Street Journal indicating that Firefly Aerospace posted a wider loss and lower revenue in its latest quarter, leading to a significant stock price drop of 15.3% on September 23, 2025 [3]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in recovering hundreds of millions of dollars for investors [4]. - The firm has been recognized for its performance in securities class action settlements, including being ranked No. 1 by ISS Securities Class Action Services in 2017 and securing over $438 million for investors in 2019 [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of aTyr Pharma, Inc. during the specified class period of the upcoming lead plaintiff deadline on December 8, 2025, for a class action lawsuit related to misleading statements about the drug Efzofitimod [1][5]. Group 1: Class Action Details - Investors who bought aTyr Pharma common stock between January 16, 2025, and September 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the court by December 8, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements, recovering hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise and reputation in handling such cases [4]. Group 3: Case Allegations - The complaint alleges that aTyr Pharma provided misleading statements regarding the efficacy of Efzofitimod, particularly concerning its ability to allow patients to taper off steroid usage completely [5]. - The lawsuit claims that when the true information became public, investors suffered damages due to the misleading nature of the statements made by the company [5].

Core Viewpoint - Rosen Law Firm is reminding investors who bought or sold Cepton, Inc. common stock between July 29, 2024, and January 6, 2025, of the December 8, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased or sold Cepton common stock during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6]. - A lead plaintiff must file a motion with the Court by December 8, 2025, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. Group 3: Case Allegations - The lawsuit alleges that during the Class Period, Cepton's defendants made materially false and misleading statements regarding the company's business and operations [5]. - Specific allegations include that Cepton received a credible third-party bid valuing the company at more than double the Koito Acquisition, which was not disclosed to shareholders [5]. - The Board of Directors allegedly failed to explore this offer meaningfully, depriving shareholders of the opportunity to consider the Koito Acquisition [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Zions Bancorporation due to allegations of materially misleading business information issued by the company [1] Group 1: Legal Action and Investor Rights - Shareholders who purchased Zions Bancorporation securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2] - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the alleged misleading information [2] Group 2: Financial Impact and Company Disclosure - On October 15, 2025, Zions Bancorporation announced a $50 million charge-off for a loan due to misrepresentations and contractual defaults by borrowers [3] - Following this announcement, Zions Bancorporation's common stock experienced a decline of 13.14% on October 16, 2025 [4] Group 3: Rosen Law Firm's Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [5] - The firm has been recognized as a leader in the field, being ranked No. 1 for securities class action settlements in 2017 and consistently in the top 4 since 2013 [5]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Hormel Foods Corporation due to allegations of materially misleading business information issued by the company [1]. Group 1: Investigation Details - The investigation is prompted by a Wall Street Journal article published on October 29, 2025, which reported that Hormel Foods cut its earnings forecast due to price pressures, bird flu, and a fire at its Arkansas peanut butter production facility [3]. - Following the news, Hormel Foods' stock experienced a significant decline of 9.1% on the same day [3]. Group 2: Class Action Information - Shareholders who purchased Hormel securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees or costs due to a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [2]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and consistently ranking among the top firms for securities class action settlements since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Synopsys, Inc. securities between December 4, 2024, and September 9, 2025, of the December 30, 2025, lead plaintiff deadline for a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Synopsys securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lead plaintiff must file a motion with the Court by December 30, 2025, to represent other class members [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company and has been ranked highly for its success in this area [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The lawsuit alleges that Synopsys made materially false and misleading statements and failed to disclose adverse facts about its business and operations [5] - Specific claims include the negative impact of Synopsys' focus on artificial intelligence customers on its Design IP business and the misleading nature of positive statements made by the company [5]

Core Viewpoint - A class action lawsuit has been filed against Perrigo Company plc for allegedly misleading investors regarding its financial health and operations, particularly concerning its infant formula business acquired from Nestlé [2][6]. Group 1: Lawsuit Details - The class action lawsuit pertains to securities purchased between February 27, 2023, and November 4, 2025, and investors must act by January 16, 2026, to serve as lead plaintiffs [2][4]. - Allegations include that Perrigo made materially false statements and failed to disclose significant underinvestment and manufacturing deficiencies in its infant formula business, leading to overstated financial results [6]. Group 2: Investor Guidance - Investors who purchased Perrigo securities during the class period may be entitled to compensation without upfront costs through a contingency fee arrangement [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [5].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Firefly Aerospace Inc. due to allegations of materially misleading business information issued to the investing public [1] Group 1: Investigation and Legal Action - Shareholders of Firefly Aerospace who purchased securities may be entitled to compensation through a contingency fee arrangement without any out-of-pocket costs [2] - A class action is being prepared by Rosen Law Firm to seek recovery of investor losses [2] Group 2: Financial Performance - Firefly Aerospace reported a wider loss and lower revenue in its latest quarter, marking its first earnings report since its stock market debut [3] - Following the earnings report, Firefly's stock fell by 15.3% on September 23, 2025 [3] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]